Drug Development

Area of Science:

• Neuroscience
• Pharmacology
• Biochemistry

Background:

• Alzheimer's disease (AD) patients treated with zervimesine (CT1812), a sigma-2 receptor (S2R) modulator, showed slowed cognitive decline in the SHINE trial.
• A significant slowing of cognitive decline (95%) was observed in a subgroup with below-median baseline plasma-pTau217 levels.

Purpose of the Study:

• To investigate the mechanisms underlying zervimesine's cognitive benefits by analyzing the cerebrospinal fluid (CSF) proteome.
• To correlate CSF protein changes with cognitive decline (ADAS-Cog11) in AD patients treated with zervimesine.

Main Methods:

• The SHINE trial was a Phase 2, randomized, double-blind, placebo-controlled study involving 152 participants over 6 months.
• CSF proteomics (TMT-MS) was performed on a subset of participants, with correlation analysis linking protein changes to ADAS-Cog11 changes.
• Pathway analyses were conducted on proteins significantly correlated with cognitive outcomes (p≤0.01).

Main Results:

• In the below-median pTau217 subgroup, 106 proteins correlated with ADAS-Cog11, enriched in amyloid biology and immune response pathways.
• Sixty-two proteins correlated with ADAS-Cog11 in both the overall (mITT) and below-median pTau217 subgroups, enriched in immune response, complement, and synapse biology pathways.
• These findings highlight specific biological pathways modulated by zervimesine that are associated with cognitive preservation.

Conclusions:

• Zervimesine's mechanism of action in Alzheimer's disease is supported by identified protein correlates related to amyloid biology in a biomarker-defined subgroup.
• The study reinforces the role of immune response and synaptic pathways in cognitive function and zervimesine's impact.
• Positive clinical outcomes and biomarker findings support the continued development of zervimesine for Alzheimer's disease treatment.